UK’s NHS Facing Major Leadership Shake-Up
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Address: 436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK,United Kingdom
Tel: +44 (0)1223 226200
Web: http://astx.com/
Astex is the world leader in fragment based drug discovery – the most important advance in drug discovery chemistry in the last 20 years.
Our internal pipeline is currently focused on the discovery and development of products in the therapeutic areas of oncology and virology.
Our pre-eminent position in this field is underlined by:
The productivity of our discovery engine which has helped to deliver seven novel drug candidates into development – five of which are now in clinical trials with another two in preclinical development.
Multiple collaborations in various therapeutic areas with leading pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica and Novartis that collectively have headline potential deal value in excess of $1 billion for Astex.
World-class science that has been published in leading journals such as Nature, Science and the Journal of Medicinal Chemistry, with some of our papers being among the most cited in their field.
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
